Latest Financial Results

Q1 2021

Quarter Ended Mar 31, 2021

Latest 10-K

View 10-K

Stock Information

Cardax, Inc.

OTCQB: CDXI

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Cardax is a consumer health company focused on marketing ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health.* Cardax previously focused on development of pharmaceuticals for diseases driven by inflammation. Cardax may seek to monetize CDX-101, the Company's pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Company's pre-clinical pharmaceutical candidate for macular degeneration.

Contact Information

Investor Relations
Cardax, Inc.
T: (808) 457-1400
investors@cardaxpharma.com

Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598